

REMARKS

These remarks are in response to the Final Office Action mailed April 4, 2008. Claims 1-10, 19, 21, 23, 27, 29-30 and 32-34 have been canceled without prejudice to Applicants' right to prosecute the canceled subject matter in any divisional, continuation, continuation-in-part or other application. No new matter is believed to have been introduced.

Claims 15-18, 22 and 24-26 have been indicated as allowable. The rejection of claims 21, 23, 29, 30 and 32-34 are moot. Applicant maintains that the animal model used by Applicant in the application demonstrates enablement for the treatment of psychiatric disorders in humans having a reduced pre-pulse inhibition comprising administering any neurotensin agonist (including PD149163). Applicant maintains, and does not disclaim in any manner, the right to file divisional or continuation applications directed to subject matter not elected (e.g., including neurotensin agonist such as PD149163 that were subject to species election).

The Director is authorized to charge any required fee or credit any overpayment to Deposit Account Number 50-4586, please reference the attorney docket number above.

The Examiner is invited to contact the undersigned at the below-listed telephone number, if it is believed that prosecution of this application may be assisted thereby.

Respectfully submitted,

GAVRILOVICH, DODD & LINDSEY LLP

Date: September 29, 2008

By: Joseph R. Baker, Jr./

Joseph R. Baker, Jr.

Registration No. 40,900

4445 Eastgate Mall, Suite 200
San Diego, California 92121
(760) 479-0474